Literature DB >> 6401695

Evidence for plasmid-mediated toxin production in Bacillus anthracis.

P Mikesell, B E Ivins, J D Ristroph, T M Dreier.   

Abstract

Large-molecular-weight plasmids were isolated from virulent and avirulent strains of Bacillus anthracis. Each strain contained a single plasmid species unique from the others with respect to molecular weight. Bacterial strains were cured of their resident extrachromosomal gene pools by sequential passage of cultures at 42.5 degrees C. Coincidental to the curing of plasmids was a loss of detectable lethal toxin and edema-producing activities and a dramatic decrease in lethal factor and protective antigen serological activities. The involvement of these plasmids in the production of toxin was firmly established by transformation of heat-passaged cells with plasmid DNA purified from the parent strain. The ability to produce parent strain levels of toxin was restored, and the plasmid DNA similar in molecular weight to that isolated from the parent was reisolated in all transformants examined. The exact role these plasmids play in the production of toxin remains to be elucidated. Two additional strains of B. anthracis, designated Pasteur vaccine strains, were examined for the ability to produce toxin and for the presence of plasmid DNA. Both strains were found to be nontoxigenic and contained no detectable plasmid elements. It is therefore likely that we, like Pasteur, cured B. anthracis strains of temperature-sensitive plasmids which code for toxin structural or regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401695      PMCID: PMC347948          DOI: 10.1128/iai.39.1.371-376.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  Purification of factor I and recognition of a third factor of the anthrax toxin.

Authors:  J L STANLEY; H SMITH
Journal:  J Gen Microbiol       Date:  1961-09

2.  Neurological and physiological responses of the primate to anthrax toxin.

Authors:  J A Vick; R E Lincoln; F Klein; B G Mahlandt; J S Walker; D C Fish
Journal:  J Infect Dis       Date:  1968-02       Impact factor: 5.226

3.  A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250.

Authors:  J J Sedmak; S E Grossberg
Journal:  Anal Biochem       Date:  1977-05-01       Impact factor: 3.365

4.  Anthrax.

Authors:  P S Brachman
Journal:  Ann N Y Acad Sci       Date:  1970-10-30       Impact factor: 5.691

5.  High frequency transformation of Bacillus subtilis protoplasts by plasmid DNA.

Authors:  S Chang; S N Cohen
Journal:  Mol Gen Genet       Date:  1979-01-05

6.  Simple agarose gel electrophoretic method for the identification and characterization of plasmid deoxyribonucleic acid.

Authors:  J A Meyers; D Sanchez; L P Elwell; S Falkow
Journal:  J Bacteriol       Date:  1976-09       Impact factor: 3.490

7.  Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis.

Authors:  F A BEALL; M J TAYLOR; C B THORNE
Journal:  J Bacteriol       Date:  1962-06       Impact factor: 3.490

8.  Anthrax. William Smith Greenfield, M.D., F.R.C.P., Professor Superintendent, the Brown Animal Sanatory Institution (1878-81). Concerning the priority due to him for the production of the first vaccine against anthrax.

Authors:  W D Tigertt
Journal:  J Hyg (Lond)       Date:  1980-12

9.  The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo.

Authors:  H SMITH; J KEPPIE; J L STANLEY
Journal:  Br J Exp Pathol       Date:  1955-10

10.  QUANTITATIVE ASSAY FOR CRUDE ANTHRAX TOXINS.

Authors:  B W HAINES; F KLEIN; R E LINCOLN
Journal:  J Bacteriol       Date:  1965-01       Impact factor: 3.490

View more
  128 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax.

Authors:  Sandip K Datta; Mojgan Sabet; Kim Phung L Nguyen; Patricia A Valdez; Jose M Gonzalez-Navajas; Shamima Islam; Ivan Mihajlov; Joshua Fierer; Paul A Insel; Nicholas J Webster; Donald G Guiney; Eyal Raz
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Swab protocol for rapid laboratory diagnosis of cutaneous anthrax.

Authors:  Leslie A Dauphin; Chung K Marston; Vinod Bhullar; Daniel Baker; Mahmudur Rahman; M Jahangir Hossain; Apurba Chakraborty; Salah Uddin Khan; Alex R Hoffmaster
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

5.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

6.  Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin.

Authors:  J W Ezzell; B E Ivins; S H Leppla
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

7.  Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.

Authors:  Angelo Scorpio; Donald J Chabot; William A Day; David K O'brien; Nicholas J Vietri; Yoshifumi Itoh; Mansour Mohamadzadeh; Arthur M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

8.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

9.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

10.  Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax.

Authors:  Cynthia A Rossi; Melanie Ulrich; Sarah Norris; Douglas S Reed; Louise M Pitt; Elizabeth K Leffel
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.